YAP1-NUTM1 Gene Fusion in Eccrine Porocarcinoma with Late Metastatic Recurrence: A Case Report


  • Sara Tormo-Mainar Department of Dermatology, Hospital del Mar-Parc de Salut Mar, Passeig Marítim, 25–29, ES-08003, Barcelona, Spain
  • Joana Vidal
  • Marta Salido
  • Ramon M. Pujol
  • Gustavo Deza




eccrine, porocarcinoma, metastatic


Abstract is missing (Short communication)


Download data is not yet available.


Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine porocarcinoma: new insights and a systematic review of the literature. Dermatol Surg 2018; 44: 1247-1261.

https://doi.org/10.1097/DSS.0000000000001566 DOI: https://doi.org/10.1097/DSS.0000000000001566

Salih AM, Kakamad FH, Baba HO, Salih RQ, Hawbash MR, Mohammed SH, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann Med Surg (Lond) 2017; 20: 74-79.

https://doi.org/10.1016/j.amsu.2017.06.027 DOI: https://doi.org/10.1016/j.amsu.2017.06.027

Sekine S, Kiyono T, Ryo E, Ogawa R, Wakai S, Ichikawa H, et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest 2019; 129: 3827-3832.

https://doi.org/10.1172/JCI126185 DOI: https://doi.org/10.1172/JCI126185

Gómez-Zubiaur A, Medina-Montalvo S, Vélez-Velázquez MD, Polo-Rodríguez I. Eccrine porocarcinoma: patient characteristics, clinical and histopathologic features, and treatment in 7 cases. Actas Dermosifiliogr 2017; 108: e27-e32.

https://doi.org/10.1016/j.adengl.2017.03.002 DOI: https://doi.org/10.1016/j.adengl.2017.03.002

Macagno N, Kervarrec T, Sohier P, Poirot B, Haffner A, Carlotti A, et al. NUT Is a specific immunohistochemical marker for the diagnosis of yap1-nutm1-rearranged cutaneous poroid neoplasms. Am J Surg Pathol 2021; 45: 1221-1227.

https://doi.org/10.1097/PAS.0000000000001693 DOI: https://doi.org/10.1097/PAS.0000000000001693

Prieto-Granada C, Morlote D, Pavlidakey P, Rodriguez-Waitkus P, Ramirez C, Florento E, et al. Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: a series of six YAP1-rearranged adnexal skin tumors. J Cutan Pathol 2021; 48: 1139-1149.

https://doi.org/10.1111/cup.14008 DOI: https://doi.org/10.1111/cup.14008

Parra O, Kerr DA, Bridge JA, Loehrer AP, Linos K. A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility. J Cutan Pathol 2021; 48: 95-101.

https://doi.org/10.1111/cup.13832 DOI: https://doi.org/10.1111/cup.13832

Russell-Goldman E, Hornick JL, Hanna J. Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma. J Cutan Pathol 2021; 48: 403-410.

https://doi.org/10.1111/cup.13924 DOI: https://doi.org/10.1111/cup.13924

Godillot C, Boulinguez S, Riffaud L, Sibaud V, Chira C, Tournier E, et al. Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. Eur J Cancer 2018; 90: 142-145.

https://doi.org/10.1016/j.ejca.2017.11.009 DOI: https://doi.org/10.1016/j.ejca.2017.11.009

Belin E, Ezzedine K, Stanislas S, Lalanne N, Beylot-Barry M, Taieb A, et al. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. Br J Dermatol 2011; 165: 985-989.

https://doi.org/10.1111/j.1365-2133.2011.10486.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10486.x

Lee KA, Cioni M, Robson A, Bataille V. Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab. BMJ Case Rep 2019; 12: e228917.

https://doi.org/10.1136/bcr-2018-228917 DOI: https://doi.org/10.1136/bcr-2018-228917



How to Cite

Tormo-Mainar, S., Vidal, J., Salido, M., Pujol, R. M., & Deza, G. (2022). YAP1-NUTM1 Gene Fusion in Eccrine Porocarcinoma with Late Metastatic Recurrence: A Case Report. Acta Dermato-Venereologica, 102, adv00752. https://doi.org/10.2340/actadv.v102.2417



Short Communication